SQZB Stock Overview
A clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
SQZ Biotechnologies Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.023 |
| 52 Week High | US$0.12 |
| 52 Week Low | US$0.01 |
| Beta | 1.46 |
| 11 Month Change | 0% |
| 3 Month Change | -61.67% |
| 1 Year Change | -53.72% |
| 33 Year Change | -99.84% |
| 5 Year Change | n/a |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%
Jun 26
We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully
Jan 05SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M
Nov 09SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology
Oct 20Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?
Aug 20SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M
Aug 04SQZ Biotechnologies names business chief as CFO
Jul 11Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook
May 17Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation
May 02Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation
Jan 11Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?
Jul 30Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)
May 16Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts
Mar 25SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 20We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth
Feb 01
Shareholder Returns
| SQZB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -1.6% |
| 1Y | -53.7% | 19.8% | 30.8% |
Return vs Industry: SQZB underperformed the US Biotechs industry which returned 19.8% over the past year.
Return vs Market: SQZB underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| SQZB volatility | |
|---|---|
| SQZB Average Weekly Movement | 70.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SQZB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SQZB's weekly volatility has increased from 52% to 70% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 53 | Howard Bernstein | www.sqzbiotech.com |
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents.
SQZ Biotechnologies Company Fundamentals Summary
| SQZB fundamental statistics | |
|---|---|
| Market cap | US$678.30k |
| Earnings (TTM) | -US$71.64m |
| Revenue (TTM) | US$12.12m |
0.1x
P/S Ratio0.0x
P/E RatioIs SQZB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SQZB income statement (TTM) | |
|---|---|
| Revenue | US$12.12m |
| Cost of Revenue | US$51.79m |
| Gross Profit | -US$39.67m |
| Other Expenses | US$31.97m |
| Earnings | -US$71.64m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.43 |
| Gross Margin | -327.29% |
| Net Profit Margin | -591.07% |
| Debt/Equity Ratio | 0% |
How did SQZB perform over the long term?
See historical performance and comparison